GSK/Adolor Entereg Gets Standard Review For Postoperative Ileus Despite Fast Track Status
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA submission was completed June 25 under FDA's continuous marketing application Pilot 1 program. There are no approved POI treatments, firm says. Chronic constipation and opioid bowel dysfunction alvimopan filings are projected for 2007.